Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mazdutide MAD study in healthy subjects
NCT03325387Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2017
- Primary completion
- Aug 2018
- Modality
- Hormonal Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and obesity comparing LY3305677 with Placebo (2 arms). Primary endpoint: Number of Participants with One or More Serious Adverse Event(s) Considered by the Investigator to be Related to Study Drug Administration. Started Oct 2017; status: completed.
02
Drugs
mazdutide
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT03325387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03325387.